Literature DB >> 28607013

penA, ponA, porB1, and mtrR Mutations and Molecular Epidemiological Typing of Neisseria gonorrhoeae with Decreased Susceptibility to Cephalosporins.

Kayo Osawa1, Katsumi Shigemura2,3, Yukie Nukata1, Koichi Kitagawa4, Fukashi Yamamichi5, Hiroyuki Yoshida1,6, Toshiro Shirakawa7,4,8, Soichi Arakawa9, Masato Fujisawa7.   

Abstract

Entities:  

Keywords:  NG-MAST; Neisseria gonorrhoeae; cephalosporins; decreased susceptibility; penA mosaic alleles

Mesh：

Substances：

Year:  2017        PMID： 28607013      PMCID： PMC5527564          DOI： 10.1128/AAC.01174-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  12 in total

1.  Emergence and spread of Neisseria gonorrhoeae clinical isolates harboring mosaic-like structure of penicillin-binding protein 2 in Central Japan.

Authors:  Masayasu Ito; Takashi Deguchi; Koh-Suke Mizutani; Mitsuru Yasuda; Shigeaki Yokoi; Shin-Ichi Ito; Yoshito Takahashi; Satoshi Ishihara; Yoshiaki Kawamura; Takayuki Ezaki
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

2.  High Prevalence of Azithromycin-Resistant Neisseria gonorrhoeae Isolates With a Multidrug Resistance Phenotype in Fukuoka, Japan.

Authors:  Masatoshi Tanaka; Ryusaburo Furuya; Shinichiro Irie; Akiko Kanayama; Intetsu Kobayashi
Journal:  Sex Transm Dis       Date:  2015-06       Impact factor: 2.830

3.  Molecular epidemiological typing within the European Gonococcal Antimicrobial Resistance Surveillance Programme reveals predominance of a multidrug-resistant clone.

Authors:  S A Chisholm; M Unemo; N Quaye; E Johansson; M J Cole; C A Ison; M J Van de Laar
Journal:  Euro Surveill       Date:  2013-01-17

4.  First nationwide study regarding ceftriaxone resistance and molecular epidemiology of Neisseria gonorrhoeae in China.

Authors:  Shao-Chun Chen; Yue-Ping Yin; Xiu-Qin Dai; Magnus Unemo; Xiang-Sheng Chen
Journal:  J Antimicrob Chemother       Date:  2015-10-15       Impact factor: 5.790

5.  Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea?: detailed characterization of the first strain with high-level resistance to ceftriaxone.

Authors:  Makoto Ohnishi; Daniel Golparian; Ken Shimuta; Takeshi Saika; Shinji Hoshina; Kazuhiro Iwasaku; Shu-ichi Nakayama; Jo Kitawaki; Magnus Unemo
Journal:  Antimicrob Agents Chemother       Date:  2011-05-16       Impact factor: 5.191

Review 6.  Drug-resistant Neisseria gonorrhoeae: latest developments.

Authors:  B Suay-García; M T Pérez-Gracia
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-02-16       Impact factor: 3.267

7.  Azithromycin resistance and its mechanism in Neisseria gonorrhoeae strains in Hyogo, Japan.

Authors:  Katsumi Shigemura; Kayo Osawa; Makiko Miura; Kazushi Tanaka; Soichi Arakawa; Toshiro Shirakawa; Masato Fujisawa
Journal:  Antimicrob Agents Chemother       Date:  2015-02-23       Impact factor: 5.191

8.  Antimicrobial resistance and molecular typing of Neisseria gonorrhoeae isolates in Kyoto and Osaka, Japan, 2010 to 2012: intensified surveillance after identification of the first strain (H041) with high-level ceftriaxone resistance.

Authors:  Ken Shimuta; Magnus Unemo; Shu-Ichi Nakayama; Tomoko Morita-Ishihara; Misato Dorin; Takuya Kawahata; Makoto Ohnishi
Journal:  Antimicrob Agents Chemother       Date:  2013-08-12       Impact factor: 5.191

9.  Mosaic-like structure of penicillin-binding protein 2 Gene (penA) in clinical isolates of Neisseria gonorrhoeae with reduced susceptibility to cefixime.

Authors:  Satoshi Ameyama; Shoichi Onodera; Masahiro Takahata; Shinzaburo Minami; Nobuko Maki; Katsuhisa Endo; Hirokazu Goto; Hiroo Suzuki; Yukihiko Oishi
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

Review 10.  Current and future antimicrobial treatment of gonorrhoea - the rapidly evolving Neisseria gonorrhoeae continues to challenge.

Authors:  Magnus Unemo
Journal:  BMC Infect Dis       Date:  2015-08-21       Impact factor: 3.090
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.